Table 2 Univariate and multivariate COX analysis of the impact of CD8, FoxP3 and TLS expression in pre- and post-preoperative chemotherapy on OS in patients with or without trastuzumab.

From: Tumor-infiltrating immune cell profiles and changes associate with additional trastuzumab in preoperative chemotherapy for patients with HER2-positive gastric cancer

   

No Trastuzumab

Trastuzumab

  

HR (95% CI)

P-value

HR (95% CI)

P-value

CD8

Pre

Total

0.999 (0.997−1.002)

0.719

0.998 (0.994−1.002)

0.424

Tumor

0.998 (0.992−1.003)

0.353

0.999 (0.995−1.003)

0.753

Stroma

1.000 (0.998−1.001)

0.661

0.998 (0.994−1.001)

0.204

Post

Total

1.000 (0.994−1.006)

0.844

0.998 (0.994−1.002)

0.358

Tumor

1.001 (0.997−1.005)

0.673

0.998 (0.995−1.002)

0.386

Stroma

0.998 (0.995−1.002)

0.354

0.998 (0.994−1.002)

0.319

FoxP3

Pre

Total

1.001 (0.992−1.010)

0.832

0.999 (0.990−1.009)

0.886

Tumor

1.006 (0.998−1.014)

0.154

1.019 (1.004−1.035)

0.014*

Tumor (Multi)a

  

1.080 (1.001−1.165)

0.047*

Stroma

0.999 (0.994−1.004)

0.581

0.995 (0.984−1.005)

0.334

Post

Total

0.986 (0.962−1.011)

0.263

0.991 (0.956−1.026)

0.597

Tumor

0.999 (0.986−1.013)

0.941

1.007 (0.981−1.033)

0.602

Stroma

0.991 (0.975−1.006)

0.248

0.985 (0.952−1.019)

0.396

TLS Density

Post

Total

1.146 (0.964−1.363)

0.123

0.992 (0.974−1.011)

0.411

Mature

1.113 (0.943−1.314)

0.205

0.923 (0.781−1.091)

0.345

Immature

1.384 (0.817−2.342)

0.227

1.003 (0.979−1.027)

0.814

in TC

0.999 (0.973−1.026)

0.948

1.149 (1.028−1.285)

0.015*

in TC(Multi)

  

1.179 (1.035−1.343)

0.013*

in IM

1.114 (0.982−1.263)

0.094

0.992 (0.973−1.011)

0.394

  1. Variables with P value less than 0.05 in univariate COX analysis and basic information of patients such as age and gender were included in the multivariate COX analysis.
  2. Significant value (P < 0.05) is in bold.
  3. aMulti, Multivariate COX analysis.
Back to article page